Anisolactone Furanocoumarin Derivative for Malaria Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-malarial drugs face challenges due to emerging drug resistance, necessitating the discovery of new active compounds to ensure a sustainable pipeline for treating malaria.
Innovation Solution
A pharmaceutical composition comprising a furanocoumarin derivative, specifically anisolactone, isolated from the leaves of Clausena lansium, is administered to treat and prevent parasitic mediated malarial disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-malarial drugs (chloroquine, pyrimethamine, quinine, artemisinin) are used to treat malaria, then malaria treatment is effective, but drug resistance is emerging and efficacy is decreasing
Solution Approach 1:
The patent changes the chemical structure parameters by isolating and characterizing novel furanocoumarin derivatives (compounds 1-10) with modified molecular structures compared to conventional drugs. The compounds feature specific substituents (R1-R6 groups) that alter their pharmacological properties, creating new mechanisms of action that overcome existing drug resistance while maintaining anti-malarial efficacy.
Solution Approach 2:
The patent extracts active anti-malarial compounds from the plant Clausena lansium through systematic isolation processes. The furanocoumarin derivatives were extracted from plant material and purified through chromatography, separating the active compounds from other plant constituents to obtain pure substances with defined anti-malarial activity.
2Adaptability or versatility
If new anti-malarial compounds are discovered from plant sources, then a sustainable pipeline of lead compounds is established, but the discovery and preparation process becomes more complex
Solution Approach 1:
The patent uses plant material (Clausena lansium) as an intermediary source to obtain novel compounds. The plant serves as a natural library containing diverse furanocoumarin structures that can be extracted and purified to create new lead compounds, bypassing the need for complex de novo synthesis while still achieving novel drug discovery.
Solution Approach 2:
The patent segments the plant material extraction process into distinct steps: crude extract preparation, fractionation by chromatography, and purification to obtain individual compounds. This systematic segmentation allows for the isolation of specific active furanocoumarin derivatives (compounds 1-10) from the complex plant matrix, making the discovery process manageable and reproducible.
3Manufacturing precision
If total synthesis is used to prepare anti-malarial drugs, then pure compounds can be obtained, but the process becomes less economical and time-consuming
Solution Approach 1:
Instead of synthesizing compounds from scratch through complex total synthesis procedures, the patent extracts pre-existing furanocoumarin derivatives directly from plant material. This extraction approach obtains pure compounds (compounds 1-10) with defined structures while significantly reducing the time and resource investment compared to multi-step synthetic pathways.
Solution Approach 2:
The patent discards the complex total synthesis process in favor of a more efficient extraction approach. By recovering and isolating the active furanocoumarin compounds directly from Clausena lansium plant material, the process eliminates the need for lengthy synthetic sequences while maintaining compound purity and obtaining valuable lead structures for drug development.
Data Source
AI summary
having core structure (A) as given below, its pharmaceutical acceptable salt, isomer or a combination thereof for treatment and/or prevention of a parasitic mediated disease. The present invention also provides a method for manufacturing and isolating said compound as well as method for treatment and prevention of parasitic mediated disease using said compound.